Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients
- APD418 currently in Phase 1 clinical investigation - data expected this year SAN DIEGO , Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation for APD418, a β 3 -adrenergic
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary
SAN DIEGO , Jan. 13, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Joan Schmidt as Executive Vice President, General Counsel and Secretary. Ms. Schmidt will join Arena formally in March 2020 and report to Amit D.
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16
SAN DIEGO , Jan. 8, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 38 th Annual J.P. Morgan Healthcare Conference on Thursday, January 16 , at 1:00 PM
View HTML
Toggle Summary Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years
- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD) - Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata (AA) - First subject dosed in APD418 Ph 1 trial in Decompensated Heart Failure (DHF) - Expanded multi-program collaboration
View HTML
Toggle Summary Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
- Selected targets (Project Cabrillo) represent new therapeutic potential across a broad range of immune and inflammatory diseases - Leveraging Beacon's world-class G protein-coupled receptor (GPCR) discovery platform to augment Arena's robust pipeline SAN DIEGO , Jan.
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Nov. 26, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: Evercore ISI HealthCONx Conference – Presenting on Tuesday, December 3 , at 11:00 AM ET in Boston
View HTML
Toggle Summary California Life Sciences Association Honors Arena Pharmaceuticals at the Pantheon 2019 DiNA™ Awards for the Deal of the Year
- Arena received the 2019 Deal of the Year Award for its global licensing agreement with United Therapeutics for ralinepag, a prostacyclin receptor agonist, in development for the treatment of pulmonary arterial hypertension (PAH) SAN DIEGO , Nov. 18, 2019 /PRNewswire/ --  Arena Pharmaceuticals,
View HTML
Toggle Summary Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS
- In a Human Mass Balance study, etrasimod metabolism demonstrated no major metabolites - The overall results suggest low risk for drug-drug interactions SAN DIEGO , Nov. 6, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance,
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will present at the upcoming investor conferences: Credit Suisse 28th Annual Healthcare Conference – Presenting on Tuesday, November 12 , at 10:00 AM ET (
View HTML
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO , Oct. 28, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML